BioMarin Pharmaceutical (BMRN) - 18 Year Stock Price History

Historical daily stock prices for BioMarin Pharmaceutical since 1999 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for BioMarin Pharmaceutical (BMRN) as of August 18, 2017 is 80.92.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $14.183B $1.117B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.